Nanobiotix SA
NBTX23.040USD
+0.390+1.72%
收盤 12/26, 16:00（美東）報價延遲15分鐘
1.11B總市值
虧損本益比TTM
關於 Nanobiotix SA 公司
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Nanobiotix SA簡介
公司代碼NBTX
公司名稱Nanobiotix SA
上市日期Oct 29, 2012
CEOLevy (Laurent)
員工數量108
證券類型Depository Receipt
年結日Oct 29
公司地址60 rue de Wattignies
城市PARIS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家France
郵編75012
電話33140260470
網址https://www.nanobiotix.com
公司代碼NBTX
上市日期Oct 29, 2012
CEOLevy (Laurent)
Nanobiotix SA公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial & Business Officer
Chief Financial & Business Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the of the Board
Independent Vice Chairwoman of the of the Board
--
--
Ms. Anne-Juliette Hermant
Ms. Anne-Juliette Hermant
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Craig West
Mr. Craig West
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Enno Spillner
Mr. Enno Spillner
Independent Director
Independent Director
--
--
Dr. Alain Herrera
Dr. Alain Herrera
Independent Director
Independent Director
--
--
Dr. Louis Kayitalire, M.D.
Dr. Louis Kayitalire, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Brandon Owens
Mr. Brandon Owens
Vice President - Strategic Marketing and Corporate Communications
Vice President - Strategic Marketing and Corporate Communications
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial & Business Officer
Chief Financial & Business Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the of the Board
Independent Vice Chairwoman of the of the Board
--
--
Ms. Anne-Juliette Hermant
Ms. Anne-Juliette Hermant
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Craig West
Mr. Craig West
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月12日 週三
更新時間: 11月12日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Johnson & Johnson Innovation-JJDC, Inc.
11.66%
Geode Capital Management, L.L.C.
0.02%
Optiver Holding B.V.
0.01%
其他
88.30%
持股股東
持股股東
佔比
Johnson & Johnson Innovation-JJDC, Inc.
11.66%
Geode Capital Management, L.L.C.
0.02%
Optiver Holding B.V.
0.01%
其他
88.30%
股東類型
持股股東
佔比
Venture Capital
11.66%
Investment Advisor/Hedge Fund
0.02%
Investment Advisor
0.02%
其他
88.30%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
27
5.65M
11.71%
-4.13M
2025Q2
25
5.76M
12.15%
-4.19M
2025Q1
25
5.76M
12.15%
-4.19M
2024Q4
25
6.07M
12.79%
-4.24M
2024Q3
21
6.42M
13.54%
-3.89M
2024Q2
22
9.30M
19.73%
-1.04M
2024Q1
21
9.31M
19.76%
-988.94K
2023Q4
21
9.28M
19.68%
+1.01M
2023Q3
16
4.47M
12.36%
+481.67K
2023Q2
12
3.47M
9.94%
-1.27M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Johnson & Johnson Innovation-JJDC, Inc.
5.62M
11.66%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
10.18K
0.02%
--
--
Jun 30, 2025
Morgan Stanley & Co. International Plc
5.30K
0.01%
-800.00
-13.11%
Jun 30, 2025
UBS Financial Services, Inc.
4.42K
0.01%
+1.42K
+47.27%
Jun 30, 2025
EverSource Wealth Advisors, LLC
517.00
0%
+517.00
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
761.00
0%
+100.00
+15.13%
Jun 30, 2025
RBC Capital Markets Wealth Management
125.00
0%
-11.00
-8.09%
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
33.00
0%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Biotechnology ETF
0%
iShares Biotechnology ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Nanobiotix SA的前五大股東是誰？
Nanobiotix SA的前五大股東如下：
Johnson & Johnson Innovation-JJDC, Inc.持有股份：5.62M佔總股份比例：11.66%。
Geode Capital Management, L.L.C.持有股份：10.18K佔總股份比例：0.02%。
Morgan Stanley & Co. International Plc持有股份：5.30K佔總股份比例：0.01%。
UBS Financial Services, Inc.持有股份：4.42K佔總股份比例：0.01%。
EverSource Wealth Advisors, LLC持有股份：517.00佔總股份比例：0.00%。
Johnson & Johnson Innovation-JJDC, Inc.持有股份：5.62M佔總股份比例：11.66%。
Geode Capital Management, L.L.C.持有股份：10.18K佔總股份比例：0.02%。
Morgan Stanley & Co. International Plc持有股份：5.30K佔總股份比例：0.01%。
UBS Financial Services, Inc.持有股份：4.42K佔總股份比例：0.01%。
EverSource Wealth Advisors, LLC持有股份：517.00佔總股份比例：0.00%。
Nanobiotix SA的前三大股東類型是什麼？
Nanobiotix SA 的前三大股東類型分別是：
Johnson & Johnson Innovation-JJDC, Inc.
Geode Capital Management, L.L.C.
Optiver Holding B.V.
Johnson & Johnson Innovation-JJDC, Inc.
Geode Capital Management, L.L.C.
Optiver Holding B.V.
有多少機構持有Nanobiotix SA(NBTX)的股份？
截至2025Q3，共有27家機構持有Nanobiotix SA的股份，合計持有的股份價值約為5.65M，占公司總股份的11.71% 。與2025Q2相比，機構持股有所增加，增幅為-0.44%。
哪個業務部門對Nanobiotix SA的收入貢獻最大？
在--，--業務部門對Nanobiotix SA的收入貢獻最大，創收--，占總收入的--% 。
